GlassScriptPhysician profile
Mohit Anand
NPI 1912976077
$2,293.25
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $891 · 2020: $760 · 2021: $562 · 2022: $80.46.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $373.81 | 2019-2021 | |
| Novo Nordisk INC | $281.19 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $227.58 | 2019-2020 | |
| Abbvie INC. | $202.73 | 2020-2022 | |
| Amarin Pharma, INC. | $142.93 | 2019-2020 | |
| Esperion Therapeutics, INC. | $114.96 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $100.87 | 2019 | |
| Merck Sharp & Dohme LLC | $98.44 | 2019-2021 | |
| Pfizer INC. | $93.26 | 2019-2021 | |
| Allergan, INC. | $64.47 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $58.06 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.89 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.31 | 2019 | |
| Janssen Pharmaceuticals, INC | $37.78 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.44 | 2020-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $31.27 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $31.12 | 2020 | |
| Neurelis, INC. | $30.82 | 2020 | |
| Glaxosmithkline, LLC. | $28.77 | 2019 | |
| Astellas Pharma US INC | $23.82 | 2019 | |
| Sk Life Science, INC. | $22.50 | 2020 | |
| Cranial Technologies, INC | $22.03 | 2019 | |
| Abbott Laboratories | $20.98 | 2019 | |
| Alexion Pharmaceuticals, INC. | $19.70 | 2019 | |
| Hologic Sales and Service, LLC | $19.64 | 2019 | |
| Vyera Pharmaceuticals, LLC | $17.54 | 2020 | |
| Sanofi Pasteur INC. | $15.55 | 2020 | |
| Advanced Respiratory, INC | $13.81 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.60 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $13.56 | 2020 | |
| Shire North American Group INC | $13.53 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $10.79 | 2019 | |
| Clarus Therapeutics INC. | $10.50 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohit Anand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.